Menu
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
• Study to evaluate potential of novel combination therapy for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC)
• Boehringer Ingelheim's IGF mAB BI 836845 and Lilly's CDK 4 and 6 inhibitor abemaciclib have shown promising early phase results in metastatic breast cancer
(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralising antibody, in combination with abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in patients diagnosed with HR+/HER2- mBC. ...
Source : http://me-newswire.net//news/18332/en...
Vendredi 20 Juin 2025 - 08:00 Tchad : Coris Bank International Tchad lance officiellement sa marque |
Mardi 10 Juin 2025 - 10:30 Tchad : à Yamba-Tchingsou, une école officielle laissée pour compte |
Mercredi 4 Juin 2025 - 08:50 Tchad : Dans la province du Lac, le Projet PROLAC accélère la transformation locale |
